Loading...
XSTOIMMNOV
Market cap10mUSD
Dec 23, Last price  
0.66SEK
1D
1.39%
1Q
-28.79%
Jan 2017
-99.28%
IPO
-97.67%
Name

Immunovia AB (publ)

Chart & Performance

D1W1MN
XSTO:IMMNOV chart
P/E
—
P/S
70.90
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.43%
Rev. gr., 5y
36.48%
Revenues
2m
+37.55%
208,8121,178,634359,165205,193177,284148,963332,595356,000362,000844,0001,145,0001,575,000
Net income
-309m
L+113.36%
-258,905-1,596,419-8,859,089-7,383,680-14,723,222-45,232,200-86,538,641-114,521,000-147,451,000-157,398,000-145,034,000-309,439,000
CFO
-147m
L-16.25%
0-414,310-8,290,625-2,843,341-11,866,824-46,317,954-84,111,307-91,952,000-120,704,000-152,648,000-175,582,000-147,057,000
Earnings
Feb 19, 2025

Profile

Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
URL
https://immunovia.com/
IPO date
Dec 01, 2015
Employees
39
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,575
37.55%
1,145
35.66%
844
133.15%
Cost of revenue
41,098
52,113
110,638
Unusual Expense (Income)
NOPBT
(39,523)
(50,968)
(109,794)
NOPBT Margin
Operating Taxes
(23,058)
1,432
Tax Rate
NOPAT
(39,523)
(27,910)
(111,226)
Net income
(309,439)
113.36%
(145,034)
-7.86%
(157,398)
6.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
121,243
639
440
BB yield
-87.41%
-0.10%
-0.02%
Debt
Debt current
2,499
4,874
6,106
Long-term debt
6,073
70,274
60,418
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(68,216)
(34,393)
(223,915)
Cash flow
Cash from operating activities
(147,057)
(175,582)
(152,648)
CAPEX
(1,061)
(1,624)
(24,184)
Cash from investing activities
3,197
(1,624)
(23,826)
Cash from financing activities
114,743
(5,107)
(5,269)
FCF
(6,763)
(29,260)
(109,053)
Balance
Cash
76,788
106,041
287,406
Long term investments
3,500
3,033
Excess cash
76,709
109,484
290,397
Stockholders' equity
(1,069,489)
(748,260)
(580,168)
Invested Capital
1,140,766
1,029,637
1,047,333
ROIC
ROCE
EV
Common stock shares outstanding
78,368
24,386
24,386
Price
1.77
-93.27%
26.30
-64.93%
75.00
-37.08%
Market cap
138,712
-78.37%
641,350
-64.93%
1,828,945
-33.27%
EV
70,496
631,263
1,606,688
EBITDA
102,196
(26,055)
(90,731)
EV/EBITDA
0.69
Interest
1,166
1,600
1,432
Interest/NOPBT